169 related articles for article (PubMed ID: 24355694)
1. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization.
Daniele A; Divella R; Quaranta M; Mattioli V; Casamassima P; Paradiso A; Garrisi VM; Gadaleta CD; Gadaleta-Caldarola G; Savino E; Maci R; Bellizzi A; Fazio V
Clin Biochem; 2014 Feb; 47(3):184-90. PubMed ID: 24355694
[TBL] [Abstract][Full Text] [Related]
2. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
3. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
4. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
5. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
Vasala K; Turpeenniemi-Hujanen T
Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
[TBL] [Abstract][Full Text] [Related]
6. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
7. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer.
Pradhan-Palikhe P; Vesterinen T; Tarkkanen J; Leivo I; Sorsa T; Salo T; Mattila PS
Oral Oncol; 2010 Jul; 46(7):514-8. PubMed ID: 20371206
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma.
Lempinen M; Lyytinen I; Nordin A; Tervahartiala T; Mäkisalo H; Sorsa T; Isoniemi H
Ann Med; 2013 Nov; 45(7):482-7. PubMed ID: 23962148
[TBL] [Abstract][Full Text] [Related]
9. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma.
Giannelli G; Bergamini C; Marinosci F; Fransvea E; Quaranta M; Lupo L; Schiraldi O; Antonaci S
Int J Cancer; 2002 Feb; 97(4):425-31. PubMed ID: 11802202
[TBL] [Abstract][Full Text] [Related]
10. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
[TBL] [Abstract][Full Text] [Related]
11. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
Hsieh MY; Lin ZY; Chuang WL
Kaohsiung J Med Sci; 2011 Aug; 27(8):314-22. PubMed ID: 21802642
[TBL] [Abstract][Full Text] [Related]
12. Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients.
El Tayebi HM; Salah W; El Sayed IH; Salam EM; Zekri AR; Zayed N; Salem ES; Esmat G; Abdelaziz AI
Biomarkers; 2011 Jun; 16(4):346-54. PubMed ID: 21506705
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
Zhang JB; Chen Y; Zhang B; Xie X; Zhang L; Ge N; Ren Z; Ye SL
Eur J Gastroenterol Hepatol; 2011 Sep; 23(9):787-93. PubMed ID: 21730869
[TBL] [Abstract][Full Text] [Related]
14. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
Poon RT; Lau C; Pang R; Ng KK; Yuen J; Fan ST
Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization.
Kim SH; Chung YH; Yang SH; Kim JA; Jang MK; Kim SE; Lee D; Lee SH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Suh DJ
Korean J Hepatol; 2009 Sep; 15(3):320-30. PubMed ID: 19783881
[TBL] [Abstract][Full Text] [Related]
16. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic significance of serum gamma-glutamyl transferase before transcatheter arterial chemoembolization in patients with intermediate hepatocellular carcinoma].
Chang Z; Wang M; Liu F; Song P; Duan F; Wang Z
Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(9):667-9. PubMed ID: 24842205
[TBL] [Abstract][Full Text] [Related]
18. [Expression and prognostic value of proliferating cell nuclear antigen in hepatocellular carcinoma patients received preoperative transcatheter arterial chemoembolization].
Guo RP; Yu WS; Wei W
Ai Zheng; 2008 Feb; 27(2):201-5. PubMed ID: 18279622
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between serum matrix metalloproteinase-2 and metastasis and recurrence following radical hepatic resection in hepatocellular carcinoma].
Niu Q; Tang Z; Ma Z; Qin L; Bao W; Zhang L
Zhonghua Gan Zang Bing Za Zhi; 2001 Jul; 9 Suppl():58-60. PubMed ID: 11509142
[TBL] [Abstract][Full Text] [Related]
20. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients.
Groblewska M; Mroczko B; Kozlowski M; Niklinski J; Laudanski J; Szmitkowski M
Folia Histochem Cytobiol; 2012; 50(4):590-8. PubMed ID: 23264224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
